1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Immunovia AB (publ)
  6. Summary
    IMMNOV   SE0006091997

IMMUNOVIA AB (PUBL)

(IMMNOV)
  Report
Real-time Estimate Cboe Europe  -  06:18 2022-08-15 am EDT
40.28 SEK   -1.76%
08/11Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray™ PanCan-d test
AQ
08/11Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California Dept of Public Health for IMMray Pancan-d Test
CI
07/05CPT PLA Code for the IMMray™ PanCan-d test approved
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
08/09/2022 08/10/2022 08/11/2022 08/12/2022 08/15/2022 Date
35.92(c) 35.64(c) 39.7(c) 41(c) 40.2 Last
16 814 34 998 117 831 46 518 14 392 Volume
-3.54% -0.78% +11.39% +3.27% -1.95% Change
More quotes
Estimated financial data (e)
Sales 2022 3,50 M 0,34 M 0,34 M
Net income 2022 -195 M -19,1 M -19,1 M
Net cash position 2022 64,0 M 6,27 M 6,27 M
P/E ratio 2022 -4,76x
Yield 2022 -
Sales 2023 92,8 M 9,09 M 9,09 M
Net income 2023 -194 M -19,0 M -19,0 M
Net cash position 2023 287 M 28,1 M 28,1 M
P/E ratio 2023 -4,80x
Yield 2023 -
Capitalization 928 M 90,9 M 90,9 M
EV / Sales 2022 247x
EV / Sales 2023 6,91x
Nbr of Employees 69
Free-Float 64,2%
More Financials
Company
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease... 
More about the company
Ratings of Immunovia AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about IMMUNOVIA AB (PUBL)
08/11Immunovia, Inc. Issued Clinical and Public Health Laboratory License from California De..
AQ
08/11Immunovia, Inc. Receives Clinical and Public Health Laboratory License from California ..
CI
07/05CPT PLA Code for the IMMray™ PanCan-d test approved
AQ
06/30The PanDIA-1 study, for early detection of pancreatic cancer in newly onset type 2 diab..
AQ
06/30Immunovia AB Announces PanDIA-1 Study for Early Detection of Pancreatic Cancer in Newly..
CI
06/27TRANSCRIPT : Immunovia AB - Special Call
CI
06/27Invitation to Immunovia's Presentation of PanFAM-1 Results
AQ
06/27PanFAM-1 Results Partly Inconclusive
AQ
06/27Immunovia AB Announces Results from PanFAM-1 Study
CI
06/02Immunovia Makes Acting President/CEO Permanent
MT
06/02Immunovia AB Announces Executive Changes
CI
06/02Philipp Mathieu appointed CEO of Immunovia AB
AQ
06/02Immunovia Names Philipp Mathieu as Chief Executive Officer
CI
05/23Immunovia, Inc. market access increases when achieving Clinical Laboratory Permits from..
AQ
05/17Immunovia, Inc. achieves Clinical Laboratory Licensure from Rhode Island Dept of Health..
AQ
More news
News in other languages on IMMUNOVIA AB (PUBL)
08/11Immunovia, Inc. reçoit une licence de laboratoire clinique et de santé publique du Cali..
06/30Immunovia AB annonce que l'étude PanDIA-1 pour la détection précoce du cancer du pancré..
06/27Immunovia AB annonce les résultats de l'étude PanFAM-1
06/02Immunovia rend permanent le président-directeur général par intérim
06/02Immunovia AB (publ) annonce des changements de direction
More news
Chart IMMUNOVIA AB (PUBL)
Duration : Period :
Immunovia AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IMMUNOVIA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 41,00 SEK
Average target price 97,50 SEK
Spread / Average Target 138%
EPS Revisions
Managers and Directors
Philipp Mathieu President & Chief Executive Officer
Hans Liljenborg Finance Director
Karin Almqvist Liwendahl Chief Financial Officer
Karl Arne Krister Borrebaeck Chairman
Rolf Bertil Ehrnström Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
IMMUNOVIA AB (PUBL)-45.33%91
SARTORIUS AG-26.04%29 732
QUIDELORTHO CORPORATION-37.71%5 630
BIOTAGE AB (PUBL)-17.71%1 394
REVENIO GROUP OYJ-11.00%1 347
SHANGHAI AOHUA PHOTOELECTRICITY ENDOSCOPE CO., LTD.28.04%956